Rapid Autopsy Protocol for Small Cell Lung Cancer
This observational study, called a pilot study, is creating a rapid autopsy program for patients with Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center. The goal is to understand the biology of SCLC better by collecting tissue samples soon after a patient passes away. Researchers will collect tissue from the lung, liver, skin, and any tumors under the skin, as well as blood samples, within 10 hours of death. This study aims to see if it's possible to set up such a program and use the collected tissues to identify biological and molecular markers of SCLC. You may be eligible if you are 18 years or older, have an active SCLC diagnosis, and provide written consent. The study's status is currently unclear.
- Study design
- This is an observational pilot study aiming to enroll 30 participants. It is not testing a drug but rather establishing a procedure for tissue collection.
- What's involved
- Participants would have biospecimens (tissue and blood) collected via rapid autopsy within 10 hours of expiration.
- Compensation
- Not stated in the trial record.
- Follow-up
- The feasibility and utilization of tissue will be measured at 5 years, but this refers to the study's overall goals, not individual participant follow-up.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer
At a glance
Conditions
Where it's being run
3 sites across 1 statesStudy leadership
- Shadia I. Jalal, MD · PRINCIPAL_INVESTIGATOR · Indiana University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Determining the Feasibility of the Creation of a Rapid Autopsy Program at IUSCCC for SCLC through enrollment and sample collections5 years
- Utilization of Tissue to Better Understand the Complex Biology of SCLC5 years
Utilize tissue obtained from rapid autopsies to generate novel patient derived xenograft models and tumor cell lines, in addition to RNA, whole exome and whole genome sequencing, protein extraction to better understand the complex biology of SCLC and set up an infrastructure to develop relevant clinical models that will allow the development of better therapies.